Bryan Kohrs
Energy Biosciences Institute(US)Caribou Biosciences (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, CRISPR and Genetic Engineering, T-cell and B-cell Immunology, Drug Transport and Resistance Mechanisms, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Harnessing type I CRISPR–Cas systems for genome engineering in human cells(2019)121 cited
- → Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells(2021)62 cited
- → High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models(2024)29 cited
- → Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness(2023)22 cited
- → Charge is Major Determinant of Activation of the Ligand‐Responsive Multidrug Resistance Gene Regulator, BmrR(2016)5 cited
- → Highly Specific Cas9 and Cas12a Engineering of Human T Cells for Generation of Novel Allogeneic Cell Therapies(2024)2 cited
- → Unconventional Coupling between Ligand Recognition and Allosteric Control in the Multidrug Resistance Gene Regulator, BmrR(2017)2 cited
- → Abstract LB009: A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection(2022)1 cited
- → Figure S7. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models(2024)
- → CB-011, a BCMA-Specific Allogeneic CAR-T Cell Therapy, Engineered with Next-Generation CRISPR Technology to Express an HLA-E Fusion Transgene to Prevent Immune Cell-Mediated Rejection, for r/r Multiple Myeloma(2023)